Muñoz R, De La Campa A G
(Consejo Superior de Investigaciones Cientificas), Centro Nacional de Biologia Celular y Retrovirus, Instituto de Salud Carlos III, Madrid, Spain.
Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7. doi: 10.1128/AAC.40.10.2252.
The genes encoding the ParC and ParE subunits of topoisomerase IV of Streptococcus pneumoniae, together with the region encoding amino acids 46 to 172 (residue numbers are as in Escherichia coli) of the pneumococcal GyrA subunit, were partially characterized. The gyrA gene maps to a physical location distant from the gyrB and parC loci on the chromosome, whereas parC is closely linked to parE. Ciprofloxacin-resistant (Cpr) clinical isolates of S. pneumoniae had mutations affecting amino acid residues of the quinolone resistance-determining region of ParC (low-level Cpr) or in both quinolone resistance-determining regions of ParC and GyrA (high-level Cpr). Mutations were found in residue positions equivalent to the serine at position 83 and the aspartic acid at position 87 of the E. coli GyrA subunit. Transformation experiments suggest that ParC is the primary target of ciprofloxacin. Mutation in parC appears to be a prerequisite before mutations in gyrA can influence resistance levels.
对肺炎链球菌拓扑异构酶IV的ParC和ParE亚基的编码基因,以及肺炎球菌GyrA亚基编码氨基酸46至172(残基编号与大肠杆菌中的相同)的区域进行了部分表征。gyrA基因定位于染色体上与gyrB和parC基因座距离较远的物理位置,而parC与parE紧密相连。肺炎链球菌的环丙沙星耐药(Cpr)临床分离株存在影响ParC喹诺酮耐药决定区氨基酸残基的突变(低水平Cpr),或ParC和GyrA的喹诺酮耐药决定区均发生突变(高水平Cpr)。在与大肠杆菌GyrA亚基第83位丝氨酸和第87位天冬氨酸等效的残基位置发现了突变。转化实验表明,ParC是环丙沙星的主要靶点。parC中的突变似乎是gyrA中的突变能够影响耐药水平之前的一个先决条件。